| Priti J Patel, MD | |
|
10400 75th St, Aurora Health Care, Kenosha, WI 53142-7884 | |
| (262) 948-7000 | |
| Not Available |
| Full Name | Priti J Patel |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 23 Years |
| Location | 10400 75th St, Kenosha, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205843067 | NPI | - | NPPES |
| 34812600 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 48617 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aurora Medical Center Kenosha | Kenosha, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aurora Medical Group, Inc. | 6709794258 | 3207 |
News Archive
Titan Pharmaceuticals, Inc. today announced that patient enrollment is now complete in the confirmatory, Phase 3 clinical study of Probuphine for the treatment of opioid addiction. This placebo and active controlled Phase 3 study is being conducted at 20 sites in the United States and the results are expected in the second quarter of 2011, about three months ahead of the original schedule.
New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas.
Porvair Sciences, in conjunction with sister company – JG Finneran Associates Inc., has produced a new informative guide to assist lab scientists select the optimum seal and closure device for different types of microplate.
Kemwell Biopharma Pvt. Ltd., a global pharmaceutical contract development and manufacturing company, announced today that its Oral Solids manufacturing facility located in Bangalore, India has successfully completed a U.S. Food and Drug Administration (USFDA) inspection.
In his latest ad audit, Kaiser Health News staff writer Jordan Rau explores whether insurers' claims, made in a recent advertisement, add up.
› Verified 4 days ago
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
Titan Pharmaceuticals, Inc. today announced that patient enrollment is now complete in the confirmatory, Phase 3 clinical study of Probuphine for the treatment of opioid addiction. This placebo and active controlled Phase 3 study is being conducted at 20 sites in the United States and the results are expected in the second quarter of 2011, about three months ahead of the original schedule.
New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas.
Porvair Sciences, in conjunction with sister company – JG Finneran Associates Inc., has produced a new informative guide to assist lab scientists select the optimum seal and closure device for different types of microplate.
Kemwell Biopharma Pvt. Ltd., a global pharmaceutical contract development and manufacturing company, announced today that its Oral Solids manufacturing facility located in Bangalore, India has successfully completed a U.S. Food and Drug Administration (USFDA) inspection.
In his latest ad audit, Kaiser Health News staff writer Jordan Rau explores whether insurers' claims, made in a recent advertisement, add up.
› Verified 4 days ago
| Entity Name | Lakeshore Medical Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003861188 PECOS PAC ID: 7719890730 Enrollment ID: O20031106000481 |
News Archive
Titan Pharmaceuticals, Inc. today announced that patient enrollment is now complete in the confirmatory, Phase 3 clinical study of Probuphine for the treatment of opioid addiction. This placebo and active controlled Phase 3 study is being conducted at 20 sites in the United States and the results are expected in the second quarter of 2011, about three months ahead of the original schedule.
New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas.
Porvair Sciences, in conjunction with sister company – JG Finneran Associates Inc., has produced a new informative guide to assist lab scientists select the optimum seal and closure device for different types of microplate.
Kemwell Biopharma Pvt. Ltd., a global pharmaceutical contract development and manufacturing company, announced today that its Oral Solids manufacturing facility located in Bangalore, India has successfully completed a U.S. Food and Drug Administration (USFDA) inspection.
In his latest ad audit, Kaiser Health News staff writer Jordan Rau explores whether insurers' claims, made in a recent advertisement, add up.
› Verified 4 days ago
| Entity Name | Aurora Advanced Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265629133 PECOS PAC ID: 3375625833 Enrollment ID: O20080123000694 |
News Archive
Titan Pharmaceuticals, Inc. today announced that patient enrollment is now complete in the confirmatory, Phase 3 clinical study of Probuphine for the treatment of opioid addiction. This placebo and active controlled Phase 3 study is being conducted at 20 sites in the United States and the results are expected in the second quarter of 2011, about three months ahead of the original schedule.
New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas.
Porvair Sciences, in conjunction with sister company – JG Finneran Associates Inc., has produced a new informative guide to assist lab scientists select the optimum seal and closure device for different types of microplate.
Kemwell Biopharma Pvt. Ltd., a global pharmaceutical contract development and manufacturing company, announced today that its Oral Solids manufacturing facility located in Bangalore, India has successfully completed a U.S. Food and Drug Administration (USFDA) inspection.
In his latest ad audit, Kaiser Health News staff writer Jordan Rau explores whether insurers' claims, made in a recent advertisement, add up.
› Verified 4 days ago
| Entity Name | Amg Illinois Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972741759 PECOS PAC ID: 8527117027 Enrollment ID: O20100129000033 |
News Archive
Titan Pharmaceuticals, Inc. today announced that patient enrollment is now complete in the confirmatory, Phase 3 clinical study of Probuphine for the treatment of opioid addiction. This placebo and active controlled Phase 3 study is being conducted at 20 sites in the United States and the results are expected in the second quarter of 2011, about three months ahead of the original schedule.
New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas.
Porvair Sciences, in conjunction with sister company – JG Finneran Associates Inc., has produced a new informative guide to assist lab scientists select the optimum seal and closure device for different types of microplate.
Kemwell Biopharma Pvt. Ltd., a global pharmaceutical contract development and manufacturing company, announced today that its Oral Solids manufacturing facility located in Bangalore, India has successfully completed a U.S. Food and Drug Administration (USFDA) inspection.
In his latest ad audit, Kaiser Health News staff writer Jordan Rau explores whether insurers' claims, made in a recent advertisement, add up.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Priti J Patel, MD Po Box 735044, Chicago, IL 60673-5044 Ph: (262) 948-7030 | Priti J Patel, MD 10400 75th St, Aurora Health Care, Kenosha, WI 53142-7884 Ph: (262) 948-7000 |
News Archive
Titan Pharmaceuticals, Inc. today announced that patient enrollment is now complete in the confirmatory, Phase 3 clinical study of Probuphine for the treatment of opioid addiction. This placebo and active controlled Phase 3 study is being conducted at 20 sites in the United States and the results are expected in the second quarter of 2011, about three months ahead of the original schedule.
New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas.
Porvair Sciences, in conjunction with sister company – JG Finneran Associates Inc., has produced a new informative guide to assist lab scientists select the optimum seal and closure device for different types of microplate.
Kemwell Biopharma Pvt. Ltd., a global pharmaceutical contract development and manufacturing company, announced today that its Oral Solids manufacturing facility located in Bangalore, India has successfully completed a U.S. Food and Drug Administration (USFDA) inspection.
In his latest ad audit, Kaiser Health News staff writer Jordan Rau explores whether insurers' claims, made in a recent advertisement, add up.
› Verified 4 days ago
Mr. John A Martini, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6308 8th Ave, Kenosha, WI 53143 Phone: 262-656-3172 | |
Dragos G Nanul, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6308 8th Avenue, Suite 2000, Kenosha, WI 53143 Phone: 262-653-5300 Fax: 262-653-5412 | |
Dr. Paul V Capelli, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 10400 75th St, Kenosha, WI 53142 Phone: 262-948-7010 Fax: 262-948-7328 | |
Rodrigo A Mata Jr., M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 6123 Green Bay Rd, Suite 120, Kenosha, WI 53142 Phone: 262-652-6995 Fax: 262-652-1370 | |
Dr. Charles Santilukka, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1020 35th St, Suite 160, Kenosha, WI 53140 Phone: 262-652-3500 | |
Dr. Vincent M Rizzo, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10400 75th St, Kenosha, WI 53142 Phone: 262-948-7080 Fax: 262-948-6818 |